BSEM — BioStem Technologies, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1658678 ·
Last close
$0.94
Market Cap
$17.93M
52W High
$8.40
52W Low
$0.90
ADV30
228,610
Next earnings
2026-11-12
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 7,640,885 4,294,088 -9,775,949 -11,375,654 43,577,416 971,145 25,250,992
Jun 2026 7,899,249 4,840,661 -8,400,687 -8,971,360 48,818,296 6,962,492 21,203,699
Sep 2025 10,473,402 9,268,608 1,448,790 761,052 62,392,843 27,158,117 12,376,434
Jun 2025 10,963,174 10,277,997 112,759 10,613 — — —

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-2,383,165
Investing CF
$-1,167,597
Financing CF
$-135,001
CapEx
$-2,417,597
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.49
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-38,965,381
Inventory
$4,711,775
Receivables
$6,621,357
ST Investments
—
EBIT TTM
$-6,839,138
Pretax Income TTM
$-7,324,678
Interest Exp TTM
—
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$31,754,082
EBITDA
$-32,577,720
Free Cash Flow
$3,721,609
Enterprise Value
$20,332,240
Total Cash
$971,145
Total Debt
$1,165,823
Shares Out
19,178,631
Trailing EPS
$0.88
Book Value
$0.98
ROE
-118.3%
ROA
-40.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2024 301,827,302 31,200,641 31,884,321 140,375,727 99,500,195 40,875,532 24,476,653
Dec 2023 16,685,405 -7,778,969 -8,482,984 14,560,291 15,904,667 -1,344,376 -3,498,960
Dec 2022 6,875,202 -4,681,548 -7,192,949 3,466,433 7,416,385 -4,076,396 303,575
Dec 2021 4,340,839 -1,605,706 -1,445,383 2,671,515 8,465,622 -5,959,398 -109,439

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$48,818,296
Forward EPS
$0.29

Peers — same industry

TickerNameMarket CapLastDaily %
ABOS Acumen Pharmaceuticals, Inc. $16.64M $0.23 —
CKDXF Opthea Ltd $14.64M $0.01 —
ESLA Estrella Immunopharma, Inc. $14.42M $0.33 —
PLUR Pluri Inc. $14.09M $0.98 —
ZIVO Zivo Bioscience, Inc. $23.18M $5.50 —

News headlines (Yahoo Finance, 1h cache)

BioStem (BSEM) Q3 2026 Earnings Call Transcript
2026-11-13 05:43 · Yahoo
BioStem Technologies, Inc. (BSEM) Reports Q3 Loss, Beats Revenue Estimates
2026-11-12 22:05 · Yahoo
BioStem Technologies Reports Third Quarter 2026 Financial Results; Grows Hospital Revenue for Second Consecutive Quarter as Customers Expand Use of Portfolio
2026-11-12 21:05 · Yahoo
BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026
2026-10-29 20:05 · Yahoo
BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options
2026-10-08 11:00 · Yahoo
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
2026-10-01 11:00 · Yahoo
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2026-09-30 12:00 · Yahoo
Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform
2026-09-21 20:30 · Yahoo
BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
2026-09-04 11:00 · Yahoo
BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal
2026-08-22 01:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.